Will Ashworth

Will Ashworth

Expertise: Public and private companies, Portfolio construction

About Will:
Will Ashworth has written about investments full-time since 2008. He loves investing and is passionate about helping others put their money to work. He particularly enjoys creating model portfolios that stand the test of time.

Publications where he’s appeared include InvestorPlace, The Motley Fool Canada, Investopedia, Kiplinger, and several others in both the U.S. and Canada. He lives in Halifax, Nova Scotia.

You can follow Will on LinkedIn. 

Recent Articles

Sensible Investors Will Ditch Acasti Pharma for Amarin 

Acasti Pharma lost $118 million in market capitalization on January 13. That makes Acasti Pharma stock a liability, not a bargain.

ADBE Stock Is All but Certain to Hit $400 This Year

Shortly after Adobe reported its Q4 2019 results in December, InvestorPlace’s Luke Lango, highlighted the many reasons the company’s stock is a long-term winner. That’s because Adobe’s captured a niche part of the cloud, ensuring that its sales continue to grow for years to come.

Teva Pharmaceutical Just Got a Little Migraine Relief 

With plans to capture 25% of the market, the nod from the FDA should help reduce the sting of having to abandon its planned use of Ajovy for cluster headaches, a move that was dropped last year after a failed phase 3 trial, which gave Eli Lilly the market to itself.

Should JD.com Follow Alibaba’s Hong Kong Listing?

JD.com’s recent bond offering and upcoming spinoff plans suggest the company might not need a secondary listing for JD stock.

Bet On Costco to Beat $312 Over/Under

Despite mean reversion and fears of recession, Oppenheimer upgraded COST to "outperform" on January 21 with a target price for Costco stock of $330.